RUXOLITINIB
ruxolitinib 5 mg tablet, 56
RUXOLITINIB (10614P)
10614P
Manner of administration:Oral
Restriction
Indication: High risk and intermediate-2 risk myelofibrosis
Treatment phase: Initial treatment
Restriction
Indication: Intermediate-1 risk myelofibrosis
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 112 | # of repeats: 0 | DPMQ: $4,675.44 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Jakavi | |||||